Close

Intercept (ICP) OCA Approval a 'Major De-Risking Event' - BMO

May 31, 2016 1:54 PM EDT Send to a Friend
BMO Capital analyst M. Ian Somaiya reiterated an Outperform Intercept Pharmaceuticals (NASDAQ: ICPT) but trimmed its price target to $219.00 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login